169 related articles for article (PubMed ID: 26500849)
21. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
22. PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironment.
Piddock RE; Loughran N; Marlein CR; Robinson SD; Edwards DR; Yu S; Pillinger GE; Zhou Z; Zaitseva L; Auger MJ; Rushworth SA; Bowles KM
Blood Cancer J; 2017 Mar; 7(3):e539. PubMed ID: 28282033
[TBL] [Abstract][Full Text] [Related]
23. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
[No Abstract] [Full Text] [Related]
24. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
25. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
[TBL] [Abstract][Full Text] [Related]
26. Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.
Pillinger G; Loughran NV; Piddock RE; Shafat MS; Zaitseva L; Abdul-Aziz A; Lawes MJ; Bowles KM; Rushworth SA
Oncotarget; 2016 Jun; 7(26):39784-39795. PubMed ID: 27174919
[TBL] [Abstract][Full Text] [Related]
27. Aspartic Aminopeptidase Is a Novel Biomarker of Aggressive Chronic Lymphocytic Leukemia.
Kakodkar P; More S; András K; Papakonstantinou N; Kelly S; Makrooni MA; Ortutay C; Szegezdi E
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32664705
[TBL] [Abstract][Full Text] [Related]
28. Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.
Shah A; Mangaonkar A
Ann Pharmacother; 2015 Oct; 49(10):1162-70. PubMed ID: 26185276
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia.
Kost SEF; Saleh A; Mejia EM; Mostafizar M; Bouchard EDJ; Banerji V; Marshall AJ; Gibson SB; Johnston JB; Katyal S
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31601046
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial.
Jones JA; Robak T; Brown JR; Awan FT; Badoux X; Coutre S; Loscertales J; Taylor K; Vandenberghe E; Wach M; Wagner-Johnston N; Ysebaert L; Dreiling L; Dubowy R; Xing G; Flinn IW; Owen C
Lancet Haematol; 2017 Mar; 4(3):e114-e126. PubMed ID: 28257752
[TBL] [Abstract][Full Text] [Related]
31. EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia.
Kosalai ST; Morsy MHA; Papakonstantinou N; Mansouri L; Stavroyianni N; Kanduri C; Stamatopoulos K; Rosenquist R; Kanduri M
Epigenetics; 2019 Nov; 14(11):1125-1140. PubMed ID: 31216925
[TBL] [Abstract][Full Text] [Related]
32. Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia.
Patel K; Pagel JM
Curr Hematol Malig Rep; 2019 Aug; 14(4):292-301. PubMed ID: 31203516
[TBL] [Abstract][Full Text] [Related]
33. Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Flinn IW; Cherry MA; Maris MB; Matous JV; Berdeja JG; Patel M
Am J Hematol; 2019 Dec; 94(12):1325-1334. PubMed ID: 31490009
[TBL] [Abstract][Full Text] [Related]
34. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic.
Fruman DA; Rommel C
Cancer Discov; 2011 Dec; 1(7):562-72. PubMed ID: 22586681
[TBL] [Abstract][Full Text] [Related]
35. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
36. Novel synthetic drugs currently in clinical development for chronic lymphocytic leukemia.
Robak P; Robak T
Expert Opin Investig Drugs; 2017 Nov; 26(11):1249-1265. PubMed ID: 28942659
[TBL] [Abstract][Full Text] [Related]
37. Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.
Amigo-Jiménez I; Bailón E; Aguilera-Montilla N; Terol MJ; García-Marco JA; García-Pardo A
Oncotarget; 2015 Dec; 6(42):44832-48. PubMed ID: 26540567
[TBL] [Abstract][Full Text] [Related]
38. Phosphatidylinositol 3-kinase β and δ isoforms play key roles in metastasis of prostate cancer DU145 cells.
Zhang Z; Liu J; Wang Y; Tan X; Zhao W; Xing X; Qiu Y; Wang R; Jin M; Fan G; Zhang P; Zhong Y; Kong D
FASEB J; 2018 Nov; 32(11):5967-5975. PubMed ID: 29792732
[TBL] [Abstract][Full Text] [Related]
39. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options.
Yeung CCS; Shadman M
Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069
[TBL] [Abstract][Full Text] [Related]
40. Elucidating the role of protein kinase C in chronic lymphocytic leukaemia.
Michie AM; Nakagawa R
Hematol Oncol; 2006 Sep; 24(3):134-8. PubMed ID: 16841369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
